Finimize - 💉 Big Pharma, big problems

Hi Reader, here's what you need to know for August 15th in 3:15 minutes.

💻 Not all tech stocks are created equal: while some are suffering at the hands of inflation, others are thriving from it. So join The Motley Fool’s Asit Sharma for How To Spot The Best Tech Stocks on Tuesday, and discover the three tech stocks that are still worth buying. Get your free ticket

Today's big stories

Investors ditched shares of major pharmaceutical companies last week ahead of a major lawsuit
Our analyst has laid out how to fix the one big mistake most investors make at times like this – Read Now
The UK economy shrank slightly less than expected in the second quarter

Big Pharma Is Headed For A Big Lawsuit

What’s Going On Here?

Shares of major pharmaceutical firms GlaxoSmithKline (GSK), Haleon, and Sanofi tumbled last week as a potentially cancer-causing drug goes to court.

What Does This Mean?

Heartburn drug Zantac was pulled from the market in 2020 when it was found to contain a cancer-causing substance, and drugmakers GSK and Sanofi have been braced for a lawsuit ever since. But if investors were shocked that Big Pharma could put profit above health, they certainly didn’t show it – until now. Legal proceedings are kicking off next week, and investors suddenly seem a lot more nervous about holding stocks that could be affected. There could be a few worth worrying about too, since Sanofi is just one of many drugmakers with rights to the drug, and there are a handful of distributors involved as well. But GSK could have the most to lose: the powerhouse first brought Zantac to the market, and its spin-off Haleon might be tarred with the same brush. Investors just ditched them all: shares of GSK, Haleon, and Sanofi fell about 10% last week.

Why Should I Care?

For markets: Bayer’s remorse.
Investors value a company based on the cash it’s expected to make in the future, so anything – including potentially billion-dollar lawsuits – that threatens those cash flows will reduce what an investor’s willing to pay for the shares today. After all, they’ve seen profit-wrecking pharma payouts before: Bayer bought agricultural biotechnology firm Monsanto for $63 billion in 2018, and ended up paying $12 billion only a couple years later to settle lawsuits around Monsanto’s weed-killer Roundup.

For you personally: Not-so-defensive stock.
This isn’t great timing: investors tend to hold healthcare stocks during recessionary times like these because they make products people need no matter what. Still, some investors will fare better than others: those who own a basket of healthcare stocks via an exchange-traded fund – rather than individual ones – are better protected against selloffs that affect a few specific companies.

You might also like: How to assess pharma companies before investing in them.

Copy to share story: https://www.finimize.com/wp/news/big-pharma-is-headed-for-a-big-lawsuit/

🙋 Ask a question

Analyst Take

How To Build A Robust Portfolio

Stéphane Renevier, Analyst

There’s one big mistake a lot of investors make.

They spend plenty of time thinking about what to include in their portfolio, and very little thinking about how much money to allocate to each position.

It’s a costly and avoidable error: you could create a much stronger portfolio just by having the right mix of assets.

And as luck would have it, there are three simple steps that can help you achieve just that.

That’s today’s Insight: how to build a more robust portfolio.

Read or listen to the Insight here

**Crypto can be loyal**

You might not have heard of loyalty tokens in crypto, and that’s a real shame.

See, they have a lot of potential: you can cash them out for real fiat, meaning they’re a closer equivalent to cold, hard cash. Thing is, few projects have zoned in on loyalty tokens so far.

Now you can unlock their full potential by collecting loyalty rewards with Verse in the same way that you rack up frequent flier points, and you can convert them into cash at any point.

Verse is set to help power the mighty Bitcoin.com ecosystem that’s already used by millions around the globe, and you can find out more about the utility token in the Verse whitepaper.

Limited Verse tokens will go on sale soon, so best get pre-approved today.

Discover Verse

The Verse token sale is not available in the U.S. and other restricted jurisdictions.